Soluble urokinase Plasminogen Activator Receptor (suPAR) serum levels are elevated in patients with neuroendocrine neoplasia

#3237

Introduction: Neuroendocrine neoplasia (NEN) represent a heterogeneous group of malignancies that might be challenging to diagnose. In case of advanced disease stages and especially in cases of poorly differentiated (G3) NEN, patients face a dismal prognosis. Therefore, innovative biomarkers allowing an early diagnosis as well as an optimal selection of suitable treatment options might help to improve clinical management of these patients.

Aim(s): Elevated serum levels of the soluble urokinase-type plasminogen activator receptor (suPAR) were recently described in very different cancers. However, the role of circulating suPAR as a biomarker in patients with NEN is unknown.

Materials and methods: In this study, we analysed serum concentrations of suPAR in a large and well-characterized cohort of 187 patients with NEN (neuroendocrine carcinomas (NEC) n = 30; neuroendocrine tumors (NET), n = 157) as well as 44 controls.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Roderburg C

Authors: Burcin �, Mohr R, Jann H, Geisler L, Tacke F,

Keywords: suPAR, neuroendocrine tumor, biomarker, prognosis,